Company Description
PAVmed Inc. operates as a medical device company in the United States.
The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay.
Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform.
The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 28, 2016 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Dr. Lishan Aklog M.D. |
Contact Details
Address: 360 Madison Avenue, 25th Floor New York, New York 10017 United States | |
| Phone | (212) 949-4319 |
| Website | pavmed.com |
Stock Details
| Ticker Symbol | PAVM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001624326 |
| CUSIP Number | 70387R106 |
| ISIN Number | US70387R4039 |
| Employer ID | 47-1214177 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lishan Aklog M.D. | Chairman and Chief Executive Officer |
| Dennis M. McGrath CPA | President, Chief Financial Officer and Corporate Secretary |
| Shaun M. O'Neill M.B.A. | Executive Vice President and Chief Operating Officer |
| Dr. Brian J. deGuzman M.D. | Executive Vice President, Chief Technology and Compliance Officer |
| Dr. Suman M. Verma M.D., Ph.D. | Senior Vice President of Molecular Genetics and Chief Scientific Officer |
| Michael Parks | Vice President of Investor Relations |
| Michael Adam Gordon | Executive Vice President, General Counsel and Secretary |
| Dr. Deepika A. Lakhani Ph.D. | Senior Vice President, Chief Regulatory and Quality Officer |
| Dr. Victoria T. Lee M.D. | Senior Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 8, 2024 | 8-K | Current Report |
| Feb 20, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | 8-K | Current Report |
| Feb 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |